Senior Director, Clinical Development at Adicet Bio

Oakland, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Candidates must hold an MD or MD/PhD degree with a minimum of six years of industry experience in clinical development within a pharmaceutical or biotechnology company. They should possess deep experience in early-stage development programs, including pre-IND and IND stages, with a strong understanding of clinical trial methodology, regulatory and compliance requirements, and experience in developing clinical strategy and study protocols.

Responsibilities

The Senior Director, Clinical Development will design and oversee early-phase clinical studies for assigned portfolio companies, translating preclinical data into clinical trial design and execution. They will support the design and implementation of clinical development plans, maintain clinical and scientific expertise, review and assess adverse events, drive go/no go decisions based on safety signals, oversee medical monitoring of ongoing trials, provide medical guidance to clinical research sites, train site staff, and address investigator questions.

Skills

Clinical Trial Design

Clinical Trial Strategy

Clinical Development

Drug Development

Protocol Development

Cross-functional Teamwork

Adicet Bio

Develops allogeneic gamma delta T cell therapies

About Adicet Bio

Adicet Bio develops cancer therapies using allogeneic gamma delta T cell therapies, which are immune cells designed to target and destroy cancer cells. Their approach utilizes donor-derived cells that are readily available, allowing for faster treatment compared to traditional methods that require a patient's own cells. The company focuses on serving healthcare providers, hospitals, and research institutions involved in cancer treatment. Adicet Bio's business model includes developing and commercializing its proprietary therapies, generating revenue through product sales and licensing agreements. A recent merger with resTORbio aims to enhance their technology and accelerate development. With significant funding, Adicet Bio is dedicated to improving cancer treatment outcomes through its unique immunotherapy approach.

Redwood City, CaliforniaHeadquarters

2014Year Founded

$141.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Wellness Program

Risks

Increased competition could impact Adicet Bio's market share.

Potential regulatory hurdles may delay clinical trials.

Financial market volatility could affect future funding rounds.

Differentiation

Adicet Bio uses allogeneic gamma delta T cells for cancer therapy.

Their therapies are 'off-the-shelf', offering faster treatment availability.

Adicet's technology includes chimeric antigen receptors for enhanced tumor targeting.

Upsides

FDA's openness to gamma delta T cell therapies could expedite approvals.

Adicet's strong financial position supports ongoing R&D efforts.

Growing market interest in gamma delta T cell therapies indicates potential collaborations.

Land your dream remote job 3x faster with AI

Try Jobo Free